Cargando…

Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer

BACKGROUND: Patient Derived Organoids (PDOs) emerged as the best technology to develop ex vivo tumor avatars. Whether drug testing on PDOs to identify efficient therapies will bring clinical utility by improving patient survival remains unclear. To test this hypothesis in the frame of clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cartry, Jérôme, Bedja, Sabrina, Boilève, Alice, Mathieu, Jacques R. R., Gontran, Emilie, Annereau, Maxime, Job, Bastien, Mouawia, Ali, Mathias, Pierre, De Baère, Thierry, Italiano, Antoine, Besse, Benjamin, Sourrouille, Isabelle, Gelli, Maximiliano, Bani, Mohamed-Amine, Dartigues, Peggy, Hollebecque, Antoine, Smolenschi, Cristina, Ducreux, Michel, Malka, David, Jaulin, Fanny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598932/ https://www.ncbi.nlm.nih.gov/pubmed/37880806 http://dx.doi.org/10.1186/s13046-023-02853-4

Ejemplares similares

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases
por: Gelli, Maximiliano, et al.
Publicado: (2023)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022)

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)

Cell clusters adopt a collective amoeboid mode of migration in confined nonadhesive environments
por: Pagès, Diane-Laure, et al.
Publicado: (2022)

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
por: Goéré, Diane, et al.
Publicado: (2018)

No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
por: Antoun, Sami, et al.
Publicado: (2019)

Synergizing liver systemic treatments with interventional oncology: friend or foe?
por: Jost, Raphaël, et al.
Publicado: (2022)

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
por: Vasseur, Damien, et al.
Publicado: (2022)

Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
por: Touloupas, Caroline, et al.
Publicado: (2021)

Genotyping Analysis of Circulating Fetal Cells Reveals High Frequency of Vanishing Twin Following Transfer of Multiple Embryos
por: Mouawia, Hussein
Publicado: (2013)

Retracted: Genotyping Analysis of Circulating Fetal Cells Reveals High Frequency of Vanishing Twin Following Transfer of Multiple Embryos
por: Mouawia, Hussein
Publicado: (2013)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume
por: Belkouchi, Younes, et al.
Publicado: (2022)

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
por: Bayle, Arnaud, et al.
Publicado: (2023)

Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol
por: Boilève, Alice, et al.
Publicado: (2020)

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
por: Auclin, Edouard, et al.
Publicado: (2021)

Comment on Cannarella et al. DNA Methylation in Offspring Conceived after Assisted Reproductive Techniques: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 5056
por: Ducreux, Bastien, et al.
Publicado: (2022)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
por: Peyraud, Florent, et al.
Publicado: (2020)

Política económica y procesos de desarrollo : la experiencia argentina entre 1976 y 1981 /
por: Sourrouille, Juan V.
Publicado: (1983)

Peroxisome Proliferator-Activated Receptors in HBV-Related Infection
por: Dubuquoy, Laurent, et al.
Publicado: (2009)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
por: Roulleaux-Dugage, Matthieu, et al.
Publicado: (2023)

Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma
por: Brunet, Maxime, et al.
Publicado: (2019)

Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients
por: Veloso Gomes, Filipe, et al.
Publicado: (2023)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy
por: Crombé, Amandine, et al.
Publicado: (2022)

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
por: Michot, Jean-Marie, et al.
Publicado: (2021)

Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)
por: Leroy, Karen, et al.
Publicado: (2023)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
por: Penel, Nicolas, et al.
Publicado: (2009)

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
por: Pierro, Monica, et al.
Publicado: (2022)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
por: Fidelle, Marine, et al.
Publicado: (2020)

Azathioprine induction of tumors with microsatellite instability: Risk evaluation using a mouse model
por: Bodo, Sahra, et al.
Publicado: (2015)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Percutaneous Ultrasound-Guided Carpal Tunnel Release: Study Upon Clinical Efficacy and Safety
por: Petrover, David, et al.
Publicado: (2016)

Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma
por: Roux, Charles, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b7bkhqqifc56v0b0isf8tmogfa